This study aimed to evaluate the association between the worst grade of facial AfR (FAfR) after initiating therapy with EGFR inhibitors and the characteristic skin type in patients with RAS wild‐type metastatic colorectal cancer enrolled in the FAEISS study (a phase III, open‐label, randomized trial evaluating topical corticosteroids for Facial Acneiform dermatitis by EGFR Inhibitors: Stepwise rank down from potent corticosteroids). The gene discussed is EGFR; the disease is metastatic colorectal cancer.